NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Millendo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.85 -0.12 (-2.41 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$4.75Now: $4.85▼$5.2550-Day Range$4.80MA: $7.21▼$9.5852-Week Range$4.56Now: $4.85▼$17.34Volume93,859 shsAverage Volume136,737 shsMarket Capitalization$88.59 millionP/E RatioN/ADividend YieldN/ABeta2.37 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMillendo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.33, Millendo Therapeutics has a potential upside of 422.3% from its current price of $4.85.Amount of Analyst CoverageMillendo Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesMillendo Therapeutics has received 67 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMillendo Therapeutics has received 71 “underperform” votes. (Add your “underperform” vote.)Community SentimentMillendo Therapeutics has received 51.45% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote “Outperform” if you believe MLND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMillendo Therapeutics does not currently pay a dividend.Dividend GrowthMillendo Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Millendo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Millendo Therapeutics is held by insiders.Percentage Held by Institutions88.21% of the stock of Millendo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Millendo Therapeutics are expected to decrease by -16.21% in the coming year, from ($2.53) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Millendo Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Millendo Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMillendo Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MLND Previous Symbol CUSIPN/A CIKN/A Webhttp://www.millendo.com/ Phone734-845-9000Debt Debt-to-Equity Ratio0.04 Current Ratio5.68 Quick Ratio5.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales305.48 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)($3.25) Net Income$-44,570,000.00 Net MarginsN/A Return on Equity-79.80% Return on Assets-64.57%Miscellaneous Employees32 Outstanding Shares18,266,000Market Cap$88.59 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive MLND News and Ratings via Email Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MLND Rates by TradingView Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions How has Millendo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MLND stock has decreased by 26.3% and is now trading at $4.85. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics. When is Millendo Therapeutics' next earnings date? Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Millendo Therapeutics. How were Millendo Therapeutics' earnings last quarter? Millendo Therapeutics Inc (NASDAQ:MLND) issued its earnings results on Wednesday, March, 11th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.06. View Millendo Therapeutics' earnings history. What price target have analysts set for MLND? 7 Wall Street analysts have issued 12 month price objectives for Millendo Therapeutics' shares. Their forecasts range from $20.00 to $35.00. On average, they expect Millendo Therapeutics' share price to reach $25.33 in the next year. This suggests a possible upside of 422.3% from the stock's current price. View analysts' price targets for Millendo Therapeutics. Has Millendo Therapeutics been receiving favorable news coverage? News coverage about MLND stock has been trending very negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMillendo Therapeutics. Are investors shorting Millendo Therapeutics? Millendo Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 266,300 shares, an increase of 67.5% from the February 27th total of 159,000 shares. Based on an average daily trading volume, of 226,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.7% of the shares of the stock are sold short. View Millendo Therapeutics' Current Options Chain. Who are some of Millendo Therapeutics' key competitors? Some companies that are related to Millendo Therapeutics include Ardelyx (ARDX), Corbus Pharmaceuticals (CRBP), Cue Biopharma (CUE), CytomX Therapeutics (CTMX), RAPT Therapeutics (RAPT), Merus (MRUS), Crinetics Pharmaceuticals (CRNX), Mirum Pharmaceuticals (MIRM), 89bio (ETNB), Kala Pharmaceuticals (KALA), XBiotech (XBIT), Viking Therapeutics (VKTX), Organogenesis (ORGO), OrganiGram (OGI) and Trillium Therapeutics (TRIL). What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Gilead Sciences (GILD), Roku (ROKU), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Applied Genetic Technologies (AGTC), Aravive (ARAV), Avid Bioservices (CDMO), Novavax (NVAX) and OrganiGram (OGI). Who are Millendo Therapeutics' key executives? Millendo Therapeutics' management team includes the following people: Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 45)Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory BoardMr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)Dr. Pharis Mohideen, Chief Medical Officer (Age 54) What is Millendo Therapeutics' stock symbol? Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND." How do I buy shares of Millendo Therapeutics? Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Millendo Therapeutics' stock price today? One share of MLND stock can currently be purchased for approximately $4.85. How big of a company is Millendo Therapeutics? Millendo Therapeutics has a market capitalization of $88.59 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe. View additional information about Millendo Therapeutics. What is Millendo Therapeutics' official website? The official website for Millendo Therapeutics is http://www.millendo.com/. How can I contact Millendo Therapeutics? Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Understanding each part of a balance sheet
